Jeff Russell
Medical Oncology · Salt Lake City, UTNPI 1790928729
Payments from drug & device makers
Across 245 payments — averaging $3016.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$122K
- Exelixis Inc.$117K
- Incyte Corporation$112K
- Regeneron$78K
- Boehringer Ingelheim Pharma GmbH & Co.kg$72K
- Boehringer Ingelheim International GmbH$59K
- plus $179K from 31 others
Across 1 payment — averaging $735.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$735
What the payments were for
- Consulting fees$51023%
- Food & beverage$1,63375%
- Education$402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 13 | $121,733 |
| Exelixis Inc. | 34 | $117,414 |
| Incyte Corporation | 95 | $111,578 |
| Regeneron | 10 | $77,659 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 6 | $72,475 |
| Boehringer Ingelheim International GmbH | 31 | $59,213 |
| Genmab U.S., Inc. | 6 | $58,800 |
| Eli Lilly | 1 | $58,345 |
| Pfizer | 2 | $52,601 |
| Boehringer Ingelheim | 7 | $3,875 |
| Novartis | 3 | $1,837 |
| Modernatx, Inc. | 1 | $1,118 |
| Merck Kgaa | 1 | $510 |
| Merck | 4 | $492 |
| Integra Lifesciences Corporation | 2 | $255 |
| Kerecis Limited | 1 | $148 |
| AstraZeneca | 3 | $129 |
| Immunocore Limited | 1 | $127 |
| Stemline Therapeutics Inc. | 1 | $119 |
| Axogen | 1 | $107 |
| Tersera Therapeutics LLC | 3 | $77 |
| Regeneron Healthcare Solutions, Inc. | 2 | $69 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Johnson & Johnson | 2 | $41 |
| Syndax Pharmaceuticals, Inc. | 1 | $27 |
| Rigel Pharmaceuticals, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $27 |
| Corcept Therapeutics | 1 | $26 |
| Taiho Oncology, Inc. | 1 | $25 |
| Bayer | 1 | $25 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| EMD Serono, Inc. | 1 | $19 |
| Novocure Inc. | 1 | $19 |
| Sobi, Inc | 1 | $16 |
| Fennec Pharmaceuticals, Inc. | 1 | $15 |
| ZOLL Circulation Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis SurgiClose$594
- INTEGRA$481
- INTEGRA DERMAL REGENERATION TEMPLATE$160
- PRIMATRIX$160
- Kerecis GraftGuide$148
- KIMMTRAK$127
- KEYTRUDA$125
- Orserdu$119
How this compares
$739,058 in reported general payments places this provider in the 70th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 39 | $35,538 |
| XareltoRivaroxaban | 12 | $11,714 |
| Levothyroxine Sodium | 45 | $630 |
| Ondansetron Hcl | 30 | $497 |
| Hydrocortisone | 13 | $432 |
| Levetiracetam | 12 | $240 |
| Prednisone | 32 | $236 |
| Prochlorperazine Maleate | 14 | $206 |
| Potassium Chloride | 13 | $174 |
| Doxycycline Hyclate | 12 | $132 |
| Gabapentin | 19 | $120 |
| Trazodone Hcl | 12 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $52,601 | $35,53839 claims |
| Johnson & JohnsonXarelto | $41 | $11,71412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 43 medical oncology providers in Utah.
Other medical oncology in Salt Lake City
- Wallace AkerleySalt Lake City$12.7M
- Stephan KendallSalt Lake City$10.2M
- Ignacio Garrido-LagunaSalt Lake City$8.8M
- William McKeanSalt Lake City$3.4M
- Bradley HunterSalt Lake City$3.3M
- Ahmad HalwaniSalt Lake City$2.3M
- Paul ShamiSalt Lake City$1.5M
- Kenneth GrossmannSalt Lake City$931K
- Martha GlennSalt Lake City$768K
- Mei WeiSalt Lake City$304K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.